dexrazoxane (zinecard) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Dexrazoxane is a cardioprotective drug used in patients with breast cancer to reduce cardiomyopathy associated with doxorubicin administration. Dexrazoxane is believed to act by two mechanisms: it inhibits DNA topoisomerase II and acts as a chelator for iron ions.   NCATS

More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$119.0200 - $275.0600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(+)-1,2-bis(3,5-dioxo-1-piperazinyl)propane | 4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione | adr-529 | cardioxane | dexrazoxan | dexrazoxane | dexrazoxane hcl | dexrazoxane hydrochloride | dexrazoxano | dexrazoxanum | dextrorazoxane | icrf-187 | (+)-(s)-4,4'-propylenedi-2,6-piperazinedione | savene | totect | zinecard

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue